Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation

被引：0
|
作者：
Patel, S. [1 ]
Zhao, S. [2 ]
Wei, L. [2 ]
Li, M. [3 ]
Bertino, E. [3 ]
Presley, C. [3 ]
Welliver, M. [3 ]
Haglund, K. [3 ]
Palmer, J. [3 ]
Arnett, A. [3 ]
Beyer, S. [3 ]
Mende, E. [3 ]
Elder, J. [3 ]
Hardesty, D. [3 ]
Shields, P. [4 ]
Carbone, D. [4 ]
Otterson, G. [4 ]
Williams, T. [3 ]
Owen, D. [4 ]
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Hematol Med Oncol, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Biostat, Columbus, OH 43210 USA
[3] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[4] Ohio State Univ, Ctr Comprehens Canc, Med Oncol, Columbus, OH 43210 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Stage III NSCLC; Brain Metastasis; Durvalumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P21.02
引用
收藏
页码：S363 / S364
页数：2
相关论文
共 50 条
  • [21] Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR
    Park, Cheol-Kyu
    Oh, Hyung-Joo
    Kim, Young-Chul
    Kim, Yong-Hyub
    Ahn, Sung-Ja
    Jeong, Won Gi
    Lee, Jeong Yeop
    Lee, Jae Cheol
    Choi, Chang Min
    Ji, Wonjun
    Song, Si Yeol
    Choi, Juwhan
    Lee, Sung Yong
    Kim, Hakyoung
    Lee, Shin Yup
    Park, Jongmoo
    Yoon, Seong Hoon
    Joo, Ji Hyeon
    Oh, In-Jae
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 1042 - 1054
  • [22] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
    Girard, N.
    Mornex, F.
    Christoph, D. C.
    Fietkau, R.
    Filippi, A. R.
    Field, J.
    Garrido Lopez, P.
    McDonald, F.
    Peters, S.
    Klein, A. B.
    Licour, M.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy
    Christoph, D. C.
    Behringer, D.
    Emde, T. O.
    Goekkurt, E.
    Laack, E.
    Mueller-Huesmann, H.
    Schuett, P.
    Schumann, C.
    Seese, B.
    Fietkau, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 212 - 212
  • [24] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC
    de Wit, M.
    Laack, E.
    Schulz, C.
    Wolff, T.
    Rueckert, A.
    Reck, M.
    Faehling, M.
    Fischer, J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S24 - S24
  • [25] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC
    Laack, H. -E.
    Schulz, C.
    Wolff, T.
    Rueckert, A.
    Reck, M.
    Faehling, M.
    Fischer, J. R.
    de Wit, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 186 - 187
  • [26] Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC
    Nassar, Amin H.
    Jayakrishnan, Ritujith
    Feng, Jamie
    Shepherd, Frances
    Adib, Elio
    Cheung, Justin M.
    Lin, Jessica J.
    Liu, Yufei
    Lin, Steven H.
    Parikh, Kaushal
    Sridhar, Arthi
    Shakya, Purnima
    Dilling, Thomas J.
    Kaldas, David
    Gray, Jhanelle E.
    Lobachov, Anastasiya
    Bar, Jair
    Luders, Heike
    Grohe, Christian
    Gupta, Shruti
    Leal, Ticiana
    Fitzgerald, Bailey
    Crowley, Fionnuala
    Fujiwara, Yu
    Marron, Thomas U.
    Wilgucki, Molly
    Reuss, Joshua
    Chen, Luxi
    Sankar, Kamya
    Aredo, Jacqueline, V
    Neal, Joel W.
    Wakelee, Heather A.
    Thummalapalli, Rohit
    Yu, Helena
    Whitaker, Ryan
    Velazquez, Ana
    Ragavan, Meera
    Cortellini, Alessio
    Kwiatkowski, David J.
    Naqash, Abdul Rafeh
    Goldberg, Sarah B.
    Kim, So Yeon
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 109 - 118
  • [27] Phase II Trial of Atezolizumab Before and After Definitive Chemoradiation for Patients with Unresectable Stage III NSCLC
    Ross, H.
    Kozono, D.
    Urbanic, J.
    Williams, T.
    Dufrane, C.
    Bara, I.
    Gandhi, M.
    Schulze, K.
    Brockman, J. M.
    Wang, X.
    Vokes, E.
    Stinchcombe, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2285 - S2286
  • [28] Early Assessment of the Safety of Durvalumab after sCRT in Patients with unresectable Stage III NSCLC (PACIFIC-6)
    Bischoff, H.
    Garassino, M. C.
    Mazieres, J.
    Delmonte, A.
    Bernabe, R.
    Perez, D.
    Sawyer, W.
    Trunova, N.
    Faivre-Finn, C.
    Reck, M.
    PNEUMOLOGIE, 2021, 75 : S15 - S15
  • [29] Early Safety Assessment of Durvalumab after sCRT in Patients with unresectable Stage III NSCLC (PACIFIC-6)
    Bischoff, H.
    Garassino, M.
    Delmonte, A.
    Bernabe, R.
    Diaz Rerez, I.
    Mazieres, J.
    Sawyer, W.
    Trunova, N.
    Faivre-Finn, C.
    Reck, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S12 - S12
  • [30] Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFRMutated NSCLC (PACIFIC-R)
    Peters, S.
    Christoph, D. C.
    Field, J. K.
    Fietkau, R.
    Filippi, A. R.
    Garassino, M.
    Garrido, P.
    McDonald, F.
    Mornex, F.
    Markman, B.
    Solomon, B. J.
    Anand, S.
    Chander, P.
    Qiao, Y.
    Girard, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S83 - S83
12345